Dana-Farber Phase 1 study explores toxicity reduction in combination of trastuzumab deruxtecan and olaparib in advanced HER2-expressing malignancies
Meeting Announcement
Updates every hour. Last Updated: 22-Jun-2026 06:15 ET (22-Jun-2026 10:15 GMT/UTC)
A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.
Learn how new research of the traces life-saving pediatric cancer treatments leave in DNA could help improve the detection and prevention of second neoplasms.
Phase I trial provides early clinical proof-of-concept supporting the combination of zedoresertib and lunresertib in certain advanced solid tumors
Zedoresertib, which targets WEE1, and lunresertib, a PKMYT1 inhibitor, are both investigational therapies that create synthetic lethality by blocking cell cycle proteins
Combination achieved notable responses in ovarian cancer at the preliminary recommended Phase II dose, with a 50% overall response rate across all patients and a 60% rate in patients with CCNE1 amplification
This combination has been granted FDA Fast Track Designation in patients with ovarian cancer harboring CCNE1 amplification, FBXW7 or PPP2R1A deleterious mutations
Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard two years, according to results from a phase II clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.